ArticleFuture science OA2026
Treatment trajectories and patterns following non-medical switching to biosimilar adalimumab in patients with hidradenitis suppurativa: a retrospective observational multicenter study from Saudi Arabia.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdalimumab is the first biologic approved for moderate-to-severe hidradenitis suppurativa (HS). Considering potential cost savings, real-world data evaluating the prescribing patterns following a switch from the originator in HS remain limited.
methodsWe conducted a retrospective multicenter observational study (2019-2025) at two hospitals in Saudi Arabia. Adult HS patients who received originator adalimumab for ≥3 months, and then switched to its biosimilar for non-medical reasons for ≥3 months were included. Descriptive statistics summarized baseline characteristics. A Wilcoxon paired test compared treatment durations, and a Sankey diagram illustrated treatment pathways.
resultsA total of 40 patients were included (median age: 26 years; 62.5% male; median BMI: 31.6). Most presented with nodules (55.0%), abscesses (47.5%), and sinus tracts (37.5%). Among all treatment actions/pathways, 22.6% represented treatment escalation to an alternative biologic, specifically secukinumab or ustekinumab. Patients who were switched from biosimilar therapy demonstrated more severe disease involvement. Median duration of originator therapy was 6.0 months versus 21.0 months for biosimilar (
conclusionIn this small real-world cohort, treatment escalation after switching to biosimilar adalimumab was observed in a subset of patients with more complex HS features. Larger studies using standardized severity measures are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.